Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Next Previous
Trial Profile

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects With Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemsidomide (Primary) ; Dexamethasone (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors C4 Therapeutics

Most Recent Events

  • 07 May 2025 According to a C4 Therapeutics media release, Complete cemsidomide Phase 1 dose escalation in NHL and present data expected in Q4 2025 and Open expansion cohort(s) in PTCL as part of the current cemsidomide Phase 1/2 trial expected in the second half of 2025.
  • 07 May 2025 According to a C4 Therapeutics media release, Present data from completed cemsidomide Phase 1 dose escalation in MM expected in Q3 2025
  • 07 May 2025 According to a C4 Therapeutics media release, cemsidomide multiple myeloma dose escalation has completed. 10 additional patients will be treated in a 100 µg QD expansion cohort to further characterize cemsidomide's safety and efficacy profile at this dose level.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top